GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » Return-on-Tangible-Asset

Mapi - Pharma (Mapi - Pharma) Return-on-Tangible-Asset : -30.79% (As of Jun. 2015)


View and export this data going back to . Start your Free Trial

What is Mapi - Pharma Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Mapi - Pharma's annualized Net Income for the quarter that ended in Jun. 2015 was $-4.56 Mil. Mapi - Pharma's average total tangible assets for the quarter that ended in Jun. 2015 was $14.82 Mil. Therefore, Mapi - Pharma's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2015 was -30.79%.

The historical rank and industry rank for Mapi - Pharma's Return-on-Tangible-Asset or its related term are showing as below:

MAPI's Return-on-Tangible-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.83
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

Mapi - Pharma Return-on-Tangible-Asset Historical Data

The historical data trend for Mapi - Pharma's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mapi - Pharma Return-on-Tangible-Asset Chart

Mapi - Pharma Annual Data
Trend Dec12 Dec13 Dec14
Return-on-Tangible-Asset
-4.46 -8.51 -49.58

Mapi - Pharma Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15
Return-on-Tangible-Asset - - -33.37 -76.12 -30.79

Competitive Comparison of Mapi - Pharma's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Mapi - Pharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mapi - Pharma's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mapi - Pharma's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Mapi - Pharma's Return-on-Tangible-Asset falls into.



Mapi - Pharma Return-on-Tangible-Asset Calculation

Mapi - Pharma's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2014 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2014 )  (A: Dec. 2013 )(A: Dec. 2014 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2014 )  (A: Dec. 2013 )(A: Dec. 2014 )
=-6.444/( (16.136+9.858)/ 2 )
=-6.444/12.997
=-49.58 %

Mapi - Pharma's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2015 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jun. 2015 )  (Q: Dec. 2014 )(Q: Jun. 2015 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jun. 2015 )  (Q: Dec. 2014 )(Q: Jun. 2015 )
=-4.562/( (9.858+19.779)/ 2 )
=-4.562/14.8185
=-30.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Jun. 2015) net income data.


Mapi - Pharma  (NAS:MAPI) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Mapi - Pharma Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Mapi - Pharma's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Mapi - Pharma (Mapi - Pharma) Business Description

Traded in Other Exchanges
N/A
Address
Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.

Mapi - Pharma (Mapi - Pharma) Headlines